
Opinion|Videos|March 25, 2025
Academic Perspectives on Treatment Decisions for BPDCN
Author(s)Marlise R. Luskin, MD, MSCE
An expert discusses how, for younger/fitter patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), treatment selection as a bridge to transplant is based on efficacy, toxicity, and response depth. Patient-specific (age, comorbidities) and systemic (drug access, center expertise) factors guide decisions. Emerging real-world evidence, such as Berning et al (ASH 2024), highlights CD123-targeted therapy’s role in optimizing response rates before allogeneic stem cell transplantation (allo-SCT).
Advertisement
Video content above is prompted by the following:
- For patients with BPDCN who are younger/fitter, how do you determine which treatment options provide the greatest benefit as a bridge to transplant?
- What patient-specific and systemic/logistical factors influence your treatment choice?
- What are your thoughts on real-world evidence that evaluates response rates with CD123/consolidative allo-SCT in BPDCN (Berning et al, ASH 2024)?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
3
FDA Oncology Update January 2026: New Horizons in Precision Medicine
4
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
5



















